<DOC>
	<DOCNO>NCT02716246</DOCNO>
	<brief_summary>Open-label , dose-escalation clinical trial scAAV9.U1a.hSGSH inject intravenously peripheral limb vein</brief_summary>
	<brief_title>Phase I/II Gene Transfer Clinical Trial scAAV9.U1a.hSGSH Mucopolysaccharidosis ( MPS ) IIIA</brief_title>
	<detailed_description>Self-complementary adeno-associated virus serotype 9 carry human SGSH gene control U1a promoter ( scAAV9.U1a.hSGSH ) deliver one time venous catheter insert peripheral limb vein . The vector deliver undiluted approximately 30 minute , light moderate sedation need . Dosing volume approximately 0.5 1 mL/kg , depend final vector product concentration subject cohort . A tapering course prophylactic enteral prednisone prednisolone administer</detailed_description>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis III</mesh_term>
	<criteria>Age 2 year old great Confirmed diagnosis MPS IIIA either two method : No detectable significantly reduced* SGSH enzyme activity leukocyte fibroblast assay . Genomic DNA analysis demonstrate homozygous compound heterozygous mutation SGSH gene Clinical history examination feature neurologic dysfunction Inability participate clinical evaluation determine PI Presence concomitant medical condition precludes lumbar puncture use anesthetic Inability safely sedate opinion clinical anesthesiologist Active viral infection base clinical observation Concomitant illness requirement chronic drug treatment opinion PI create unnecessary risk gene transfer Subjects antiAAV9 antibody titer â‰¥ 1:50 determined ELISA bind immunoassay Serology consistent exposure HIV , serology consistent active hepatitis A , B C infection Bleeding disorder medical condition circumstance lumbar puncture ( collection CSF ) contraindicate accord local institutional policy Visual hearing impairment sufficient preclude cooperation neurodevelopmental test Uncontrolled seizure disorder , due requirement multiple MRI examination part study protocol . Subjects stable anticonvulsive medication may include Any item ( brace , etc . ) would exclude patient able undergo MRI accord local institutional policy Any item ( brace , etc . ) would exclude patient able undergo MRI accord local institutional policy Patients cardiomyopathy significant congenital heart abnormalities The presence significant nonMPS IlIA relate CNS impairment behavioral disturbance would confound scientific rigor interpretation result study Abnormal , clinically significant laboratory value base upon normal value Nationwide Children 's Hospital Laboratory list Table 1 protocol . Due nature enzyme activity test , normal range report unit vary lab lab . Many laboratory utilize control sample rather normal range , account influence small daytoday fluctuation laboratory environment . For purpose invitation screen visit , accept `` significantly reduce '' result interpret clinical laboratory approve perform diagnostic test . For uniformity data analysis , confirmation accurate diagnosis gene transfer , subject consent complete screen visit blood drawn confirmatory enzyme activity level perform Greenwood Genetics Center Biochemical Laboratory . Subjects must enzyme activity level consider affected range Greenwood Genetic Center Biochemical Laboratory proceed within study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MPS IIIA</keyword>
</DOC>